Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 36Leukemia 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Gastrointestinal Stromal Tumors 13Leukemia, Myeloid, Chronic-Phase 12Leukemia, Myeloid 6Brain Neoplasms 6Prostatic Neoplasms 5Philadelphia Chromosome 5Blast Crisis 5Sarcoma 4Recurrence 4Glioblastoma 4Carcinoma, Non-Small-Cell Lung 4Bone Marrow Diseases 4Ovarian Neoplasms 3Melanoma 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Hematologic Diseases 3Bronchiolitis Obliterans Syndrome 3Breast Neoplasms 3Stomach Neoplasms 2Polycythemia Vera 2Neurofibromatoses 2Neoplasms by Histologic Type 2Neoplasms 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Meningioma 2

Interventions

nilotinib 1Imatinib Mesylate 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hypereosinophilic Syndrome × Imatinib Mesylate × Clear all
NCT00038675 2022-01-04

Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate

M.D. Anderson Cancer Center

Phase NA Completed
125 enrolled 9 charts
MyeloidOther hematologic neoplasm

Leukemia, Mastocytosis, Polycythemia Vera, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡